Amalgamated Bank Intercept Pharmaceuticals, Inc. Transaction History

Amalgamated Bank

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$9.99 - $18.71 $17,342 - $32,480	1,736 Added 46.0%	5,510 $102,000
Q2 2023 Aug 11, 2023	BUY	$9.17 - $19.29 $3,071 - $6,462	335 Added 9.74%	3,774 $41,000
Q1 2023 May 02, 2023	SELL	$12.53 - $21.71 $6,415 - $11,115	-512 Reduced 12.96%	3,439 $46,000
Q3 2022 Nov 09, 2022	BUY	$12.21 - $19.7 $732 - $1,182	60 Added 1.54%	3,951 $55,000
Q2 2022 Aug 15, 2022	SELL	$11.23 - $19.59 $2,100 - $3,663	-187 Reduced 4.59%	3,891 $54,000
Q1 2022 Jun 30, 2022	BUY	$13.37 - $17.79 $54,522 - $72,547	4,078 New	4,078 $66,000
Q2 2020 Aug 10, 2020	SELL	$46.7 - $92.04 $210,710 - $415,284	-4,512 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$48.35 - $118.68 $9,138 - $22,430	-189 Reduced 4.02%	4,512 $284,000
Q4 2019 Feb 13, 2020	BUY	$57.36 - $124.1 $18,297 - $39,587	319 Added 7.28%	4,701 $583,000
Q3 2019 Nov 13, 2019	SELL	$58.69 - $80.46 $3,697 - $5,068	-63 Reduced 1.42%	4,382 $291,000
Q2 2019 Aug 14, 2019	BUY	$77.77 - $120.68 $86,869 - $134,799	1,117 Added 33.56%	4,445 $354,000
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $12,121 - $15,929	132 Added 4.13%	3,328 $372,000
Q4 2018 Feb 15, 2019	BUY	$85.79 - $126.46 $274,184 - $404,166	3,196 New	3,196 $322,000
Q3 2018 Nov 14, 2018	SELL	$88.49 - $127.55 $295,291 - $425,634	-3,337 Closed	0 $0
Q2 2018 Jul 18, 2018	SELL	$60.0 - $85.67 $29,640 - $42,320	-494 Reduced 12.89%	3,337 $280,000
Q1 2018 May 22, 2018	BUY	$52.72 - $67.25 $13,021 - $16,610	247 Added 6.89%	3,831 $236,000
Q4 2017 Feb 13, 2018	BUY	$58.2 - $72.76 $208,588 - $260,771	3,584	3,584 $209,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.